Additionally, bispecific antibodies co-conjugated with Glypican-3 (GPC3) and CD47 have shown promise in enhancing the innate immune response, indicating their potential for improving HCC treatment (Du et al., 2021). The gene discussed is CD47; the disease is hepatocellular carcinoma.